Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
47.07M | 78.59M | 46.83M | 72.83M | 34.03M | Gross Profit |
47.07M | -110.49M | 43.85M | 70.44M | -28.07M | EBIT |
-261.63M | -165.53M | -161.26M | -100.53M | -46.30M | EBITDA |
-216.24M | -143.20M | -151.66M | -97.64M | -43.72M | Net Income Common Stockholders |
-223.86M | -146.96M | -151.83M | -98.00M | -43.95M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
488.74M | 374.88M | 559.49M | 567.61M | 458.73M | Total Assets |
978.03M | 575.76M | 603.13M | 605.90M | 487.18M | Total Debt |
87.76M | 84.67M | 17.34M | 17.96M | 17.99M | Net Debt |
-32.49M | -25.29M | -51.06M | -30.01M | -13.01M | Total Liabilities |
142.42M | 180.79M | 112.98M | 146.27M | 203.29M | Stockholders Equity |
835.62M | 394.97M | 490.15M | 459.64M | 283.89M |
Cash Flow | Free Cash Flow | |||
-207.34M | -137.31M | -155.92M | -130.54M | 79.03M | Operating Cash Flow |
-194.50M | -102.83M | -153.09M | -128.95M | 88.13M | Investing Cash Flow |
-404.08M | 139.89M | 20.52M | -99.83M | -422.59M | Financing Cash Flow |
608.85M | 4.19M | 153.00M | 250.28M | 289.26M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $3.55B | ― | -214.50% | ― | 29.01% | 23.93% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
48 Neutral | $2.16B | ― | -36.38% | ― | -40.11% | -17.79% | |
46 Neutral | $3.63B | ― | -19.20% | ― | -89.95% | -123.71% | |
44 Neutral | $570.81M | ― | -35.41% | ― | -39.92% | 7.38% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
39 Underperform | $962.71M | ― | -54.00% | ― | 59.55% | 3.09% |
On March 3, 2025, Kymera Therapeutics’ Board and Compensation Committee approved the grant of performance stock units (PSUs) to key employees, including executives, under the company’s 2020 Stock Option and Incentive Plan. These PSUs will vest in three installments based on achieving specific clinical milestones, potentially impacting employee incentives and aligning them with the company’s clinical development goals.
On January 14, 2025, Kymera Therapeutics announced its 2025 objectives and strategy, focusing on advancing its immunology programs, particularly the investigational oral degrader KT-621. The company is conducting a Phase 1 trial for KT-621, with plans to move into Phase 1b and 2b trials by late 2025 and early 2026, targeting conditions like atopic dermatitis and asthma. Kymera is also set to introduce a novel oral immunology program in the first half of 2025. The announcements highlight the company’s commitment to expanding its pipeline and leveraging targeted protein degradation to offer biologics-like oral therapies, positioning itself as a leader in the field.